June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Rare Variant Pathway Analysis in the Age-Related Eye Disease Study 2
Author Affiliations & Notes
  • Alexandra Pietraszkiewicz
    Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, NIH, Bethesda, Maryland, United States
  • Freekje Van Asten
    Epidemiology & Clinical Applications, National Eye Institute, NIH, Bethesda, Maryland, United States
    Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, NIH, Bethesda, Maryland, United States
  • Alan Kwong
    Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States
  • Rinki Ratnapriya
    Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, NIH, Bethesda, Maryland, United States
  • Goncalo Abecasis
    Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States
  • Anand Swaroop
    Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, NIH, Bethesda, Maryland, United States
  • Emily Chew
    Epidemiology & Clinical Applications, National Eye Institute, NIH, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Alexandra Pietraszkiewicz, None; Freekje Van Asten, None; Alan Kwong, None; Rinki Ratnapriya, None; Goncalo Abecasis, None; Anand Swaroop, None; Emily Chew, None
  • Footnotes
    Support  HHS-N-260-2005-00007-C, N01-EY-5-0007
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1833. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Alexandra Pietraszkiewicz, Freekje Van Asten, Alan Kwong, Rinki Ratnapriya, Goncalo Abecasis, Anand Swaroop, Emily Chew; Rare Variant Pathway Analysis in the Age-Related Eye Disease Study 2. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1833.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : AMD is a clinically heterogeneous disease, and GWAS studies have implicated a number of biological pathways that may underlie the variation in AMD pathogenesis and observed phenotypes. Identification of rare variants at risk loci helps to determine causative genes. Here, we collapsed rare variants into pathways and studied their association to clinical phenotypes in a subset of AREDS 2 participants who underwent whole-genome-sequencing (WGS) (n=1503).

Methods : Loss of function rare variants (stop-gain, frameshift, essential splice site, or start-loss; allele frequency <0.1% in the study population) at the 34 known AMD loci were identified from WGS data and annotated with VEP build 86 using GRCh37 coordinates and RefSeq genes. Genes were grouped into the following pathways by searching the NCBI Gene database for functional information and validating in Reactome: complement, ECM, lipids, cell survival, cell signaling, immune system, visual, and a final category including variants of unknown significance. Phenotypes analyzed include advanced AMD, geographic atropy (GA), central geographic atrophy (CGA), choroidal neovascularization (CNV), drusen area, reticular drusen, and calcified drusen.

Results : This study identified rare variants in 15.7% of AREDS 2 participants, and there was an association between the presence of rare variants and late AMD, as measured by increased AREDS scale score (p=0.025). The following pathway-phenotype associations were observed: complement and CGA (p=0.014; OR=4.218), complement and calcified drusen (p=0.02; OR=3.92), cell survival and CNV (p=0.045; OR=1.612), ECM and GA (p=0.035; OR=2.459), lipids and drusen area (p=0.003), and rare variants in the unknown category and late AMD (p=0.023; OR 1.756).

Conclusions : This study supports the hypothesis that variation in biological pathways drives the development of heterogeneous clinical phenotypes in AMD, similar to results of previous studies of complement and GA. Our analysis revealed a novel association between the development of CNV and rare variants in the cell survival pathway. Surprisingly, we found a protective effect of rare variants in the lipids pathway on drusen area. Further studies are needed to elucidate the role of rare variants in other pathways.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×